Ask AI
CAR T Cell Data From Summer Conferences

CME

Congress to Clinic: Clinical Advances Journal Club on Emerging CAR T-Cell Therapy Data From Summer Conferences ASCO, EHA, and ICML

Physicians: Maximum of 0.75 AMA PRA Category 1 Credit

Released: September 08, 2025

Expiration: March 07, 2026

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

What was the primary result of lisocabtagene maraleucel for MZL in the phase II TRANSCEND FL study?

2.

Which of the following patients may be a candidate for treatment with arlocabtagene autoleucel in the ongoing phase III QUINTESSENTIAL-2 trial?

3.

Patient Case: 62-Yr-Old Woman With R/R MM



  • A 62-yr-old woman with multiple myeloma was previously treated for newly diagnosed disease with quad-based therapy

    • Treatment included a CD38 mAb, a proteasome inhibitor, and an immunomodulatory agent



  • She is now experiencing relapse while on lenalidomide maintenance

Based on current indications, which CAR T-cell therapy is the most appropriate treatment option for this patient?